Cargando…

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission

Detalles Bibliográficos
Autores principales:	Pinkevych, Mykola, Cromer, Deborah, Tolstrup, Martin, Grimm, Andrew J., Cooper, David A., Lewin, Sharon R., Søgaard, Ole S., Rasmussen, Thomas A., Kent, Stephen J., Kelleher, Anthony D., Davenport, Miles P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999226/ https://www.ncbi.nlm.nih.gov/pubmed/27561082 http://dx.doi.org/10.1371/journal.ppat.1005745

Ejemplares similares

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2015)

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days
por: Pinkevych, Mykola, et al.
Publicado: (2016)

Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design
por: Lau, Jillian S Y, et al.
Publicado: (2022)

Predictors of SIV recrudescence following antiretroviral treatment interruption
por: Pinkevych, Mykola, et al.
Publicado: (2019)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Preferential selection of viral escape mutants by CD8(+) T cell ‘sieving’ of SIV reactivation from latency
por: Docken, Steffen S., et al.
Publicado: (2023)

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
por: Gunst, Jesper D, et al.
Publicado: (2019)

The role of latency reversal in HIV cure strategies
por: Tanaka, Kiho, et al.
Publicado: (2022)

Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium
por: Eyal, Nir, et al.
Publicado: (2019)

Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies
por: Delannoy, Aurélie, et al.
Publicado: (2019)

Modeling the Dynamics of Plasmodium vivax Infection and Hypnozoite Reactivation In Vivo
por: Adekunle, Adeshina I., et al.
Publicado: (2015)

HIV-1 Mutation and Recombination Rates Are Different in Macrophages and T-cells
por: Cromer, Deborah, et al.
Publicado: (2016)

HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat
por: Zuwala, Kaja, et al.
Publicado: (2016)

Bioinformatics and HIV Latency
por: Ciuffi, Angela, et al.
Publicado: (2015)

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials
por: Rasmussen, Thomas A., et al.
Publicado: (2013)

HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper
por: Fidler, S., et al.
Publicado: (2020)

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
por: Rasmussen, Thomas Aagaard, et al.
Publicado: (2013)

Removing One Barrier to Protecting Sex Partners in HIV Remission Studies With a Treatment Interruption
por: Eyal, Nir
Publicado: (2019)

RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency
por: Méndez, Catalina, et al.
Publicado: (2018)

The BAF complex and HIV latency
por: Mahmoudi, Tokameh
Publicado: (2012)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach
por: Eyal, Nir
Publicado: (2019)

HIV remission trial investigators’ attitudes towards risk and risk mitigation in trials that include treatment interruption
por: Okumu, Eunice Akinyi, et al.
Publicado: (2023)

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues
por: Denton, Paul W., et al.
Publicado: (2019)

Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings
por: Lau, Jillian SY., et al.
Publicado: (2021)

Limitations of dual‐fluorescent HIV reporter viruses in a model of pre‐activation latency
por: Kim, Youry, et al.
Publicado: (2019)

The Dynamics of Naturally Acquired Immunity to Plasmodium falciparum Infection
por: Pinkevych, Mykola, et al.
Publicado: (2012)

Time-to-infection by Plasmodium falciparum is largely determined by random factors
por: Pinkevych, Mykola, et al.
Publicado: (2015)

Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency
por: Zerbato, Jennifer M., et al.
Publicado: (2021)

Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells
por: Saleh, Suha, et al.
Publicado: (2011)

Chromatin, gene silencing and HIV latency
por: Mok, Hoi-Ping, et al.
Publicado: (2007)

Latency: the hidden HIV-1 challenge
por: Marcello, Alessandro
Publicado: (2006)

Molecular Understanding of HIV-1 Latency
por: Abbas, W., et al.
Publicado: (2012)

HIV-1 latency in activated T-cells
por: Berkhout, Ben
Publicado: (2013)

HIV-1 Latency in Monocytes/Macrophages
por: Kumar, Amit, et al.
Publicado: (2014)

HIV-1 transcription and latency: an update
por: Van Lint, Carine, et al.
Publicado: (2013)

Insights into the HIV Latency and the Role of Cytokines
por: Hokello, Joseph, et al.
Publicado: (2019)

β-catenin regulates HIV latency and modulates HIV reactivation
por: Barbian, Hannah J., et al.
Publicado: (2022)

HIV Latency and Nanomedicine Strategies for Anti-HIV Treatment and Eradication
por: Andre, Mickensone, et al.
Publicado: (2023)

Diverse effects of interferon alpha on the establishment and reversal of HIV latency
por: Van der Sluis, Renée M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h0u97j35irq1r1oqdq6rk6vfmi